报价延迟最少15分钟:2025/07/17 16:46 EDT
盘后时段
|
||||
|
23.62 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
23.62
|
|
|
| 价值评估 |
|
盈利(现时/预测)
119.02/-2.14
|
|
企业价值
348.81M
|
| 资产负债 |
|
每股账面净值
6.52
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
200.00K
|
|
每股收益
0.89
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/17 16:46 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function. |
